Citigroup Maintains Neutral on Charter Communications, Raises Price Target to $425

Citigroup analyst Michael Rollins maintains Charter Communications (NASDAQ:CHTR) with a Neutral and raises the price target from $400 to $425.

byBenzinga Newsdesk

January 31, 2023

1 minute read

Citigroup analyst Michael Rollins maintains Charter Communications (NASDAQ:CHTR) with a Neutral and raises the price target from $400 to $425.

Boeing Analysts Recommend Caution Following Latest 787 Production Problems

By Wayne Duggan

February 24, 4:19 PM

Boeing Co (NYSE: BA) shares dropped 4.8% on Friday after the company announced it had once again run into production problems with its 787 Dreamliner.

Analyst Ratings

Where Guidewire Software Stands With Analysts

By Benzinga Insights

December 1, 8:04 AM

Analysts have provided the following ratings for Guidewire Software (NYSE:GWRE) within the last quarter: Bullish Somewhat Bullish Indifferent…

GWRE

Ubiquiti Q3 EPS $0.83 Down From $2.30 YoY, Sales $358.07M Down From $467.24M YoY

By Benzinga Newsdesk

May 6, 7:13 AM

Ubiquiti (NYSE:UI) reported quarterly earnings of $0.83 per share. This is a 63.91 percent decrease over earnings of $2.30 per share from the same period last year. The company reported $358.07 million in sales this

Adaptimmune To Present Updated Data From Phase 1 SURPASS Trial At European Society For Medical Oncology Annual Meeting

By Bill Haddad

September 13, 7:02 AM

Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in cell therapy to treat cancer, announced updated data from its Phase 1 SURPASS trial in multiple solid tumors to be presented in a digital poster at the

ADAP

Citigroup Maintains Neutral on Charter Communications, Raises Price Target to $425

Related Posts

Boeing Analysts Recommend Caution Following Latest 787 Production Problems

Where Guidewire Software Stands With Analysts

Ubiquiti Q3 EPS $0.83 Down From $2.30 YoY, Sales $358.07M Down From $467.24M YoY

Adaptimmune To Present Updated Data From Phase 1 SURPASS Trial At European Society For Medical Oncology Annual Meeting